The short version
Ipamorelin is one of the cleanest and most selective growth hormone secretagogues studied to date. Where older GH-releasing compounds also significantly raised cortisol and prolactin — creating a less desirable side-effect profile — Ipamorelin stimulates GH release with minimal impact on those other hormones. It is most commonly studied paired with CJC-1295 as a complementary GH-optimisation stack, but it also has a research profile as a standalone compound. It is not approved for human use and is prohibited in tested sport.
How it works — in plain English
Ipamorelin binds to the ghrelin receptor (GHSR-1a) on cells in the pituitary gland, which signals for a pulse of growth hormone release. It works independently from the GHRH pathway — meaning it can stimulate GH even when the GHRH signal is absent. Its selectivity for GH over cortisol and prolactin is what distinguishes it from older secretagogues like GHRP-2 and GHRP-6, which caused hunger, facial flushing and cortisol spikes. Ipamorelin causes minimal of these effects at research doses.
What the research shows
- Preclinical studies consistently demonstrate selective, dose-dependent GH release without meaningful cortisol or prolactin elevation — the key mechanistic advantage.
- Animal models show downstream IGF-1 increases consistent with GH pathway activation.
- In research contexts, Ipamorelin is frequently studied alongside CJC-1295 to produce dual-pathway GH stimulation — see the CJC-1295 & Ipamorelin page for the combined stack evidence.
- Large-scale human safety and efficacy trials have not been published.